Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 8;11:754768. doi: 10.3389/fonc.2021.754768

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Peng, Lu, Xia, Hong, Selvaggi, Stebbing, Sun and Liang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Bayesian ranking profiles of comparable treatments on efficacy for patients with advanced ALK-positive NSCLC. Profiles indicate the probability of each comparable treatment being ranked from first to last on PFS, OS, risk of CNS progression, grade ≥3 adverse events, and serious adverse events. Ranking curves are described according to the Bayesian ranking results presented in Table S2 . ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer; PFS, progression-free survival; OS, overall survival; CNS, central nervous system.